Business Wire

CA-MATRIXX-SOFTWARE

11.6.2019 10:02:11 CEST | Business Wire | Press release

Share
Roshan Selects MATRIXX Software to Usher in Afghanistan’s Digital Era in Telecommunications

MATRIXX Software , an innovation powerhouse committed to transforming global commerce, today announced that Roshan, Afghanistan’s leading telecommunications service provider, has selected MATRIXX Digital Commerce to transform their operations and grow revenue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005211/en/

Roshan is partnering with MATRIXX Software to change the way its six million customers use telecom services by bringing real-time digital experience and personalization for all voice, data and digital services.

MATRIXX has a global customer footprint across Europe, the Middle East, Asia and North America. Roshan selected MATRIXX because it is the only vendor providing a single platform that both protects and grows revenues from traditional prepaid voice and messaging services while also delivering the tools to attract smartphone users and increase data usage. As the digital revolution sweeps through emerging markets, mobile operators need cost effective, scalable solutions that improve their existing operating portfolios while building for the future of smartphones and digital service revenues.

In a signing ceremony in Dubai, UAE, Roshan’s CEO Karim Khoja said, “Since our founding, Roshan has always embraced implementing new technologies and applications to provide our customers with the best experience. This partnership with MATRIXX Software showcases that the digital experience is quickly becoming a reality in Afghanistan.”

“Afghanistan’s communications infrastructure has come a long way in 16 years and Roshan has played and continues to play a significant role in making that happen,” said Dave Labuda, MATRIXX Software co-founder and CEO. “It is only natural that Roshan is leading the way into a new era of digital connectivity. We are proud to be a part of helping Roshan deliver the future of customer experience and service innovation that Roshan aims to bring to their customers.”

Built entirely from scratch, the multi-patented, award-winning MATRIXX Digital Commerce Platform enables a digital-first reinvention of Telco BSS. It brings together traditionally separate network and IT functions into a single platform including product design and lifecycle management, customer engagement, service delivery and monetization. Built for digital, the MATRIXX Digital Commerce Platform offers operators the agility and seamless scalability required to compete and win now and in the future.

Roshan has always been a pioneer in leveraging its robust network infrastructure and technology to support the government and the people of Afghanistan. These include the launch of Afghanistan’s first ever mobile money service, M-Paisa, which has contributed to increasing financial transparency and financial inclusion. Roshan also launched the first Telemedicine program in Afghanistan in 2007, linking hospitals in Badakhshan, Bamiyan and Kandahar provinces to the French Medical Institute for Children and Mothers (FMIC) in Kabul, one of the most modern hospitals in the country. Since its launch, almost 30,000 patients across Afghanistan have received treatment through this telemedicine link.

About Roshan

Roshan (Telecom Development Company Afghanistan Ltd) is Afghanistan's leading total communications provider with 6 million active subscribers and a network that covers over 287 districts and cities in all of the country's 34 provinces.

Roshan is a true Afghanistan success story, serving as a catalyst for economic growth and actively contributing to the country’s long-term development. Since its inception in 2003, Roshan has invested approximately $750 million in Afghanistan and is the country’s single largest private investor and taxpayer, contributing approximately five percent of the Afghan government's overall domestic revenue. Roshan directly employs around 900 people, 20 percent of whom are women, and provides indirect employment to more than 35,000 people. Roshan is deeply committed to Afghanistan’s reconstruction and development.

The Aga Khan Fund for Economic Development (AKFED), part of the Aga Khan Development Network (AKDN), is a major shareholder of Roshan and promotes private initiatives and building economically sound enterprises in the developing world. Also owned in part by Monaco Telecom International (MTI) and Telia, Roshan brings international expertise to the country and is committed to the highest standards of network quality and coverage for the people of Afghanistan.

To learn more about Roshan visit www.roshan.af or http://www.facebook.com/RoshanConnects . You can also follow us on Twitter @roshanconnects .

About MATRIXX Software

MATRIXX Software provides next-generation, cloud native digital commerce solutions that transform how companies do business. Serving many of the world’s largest communications companies, IoT players and emerging digital service providers, MATRIXX is committed to delivering a modern commerce platform that easily scales to support global market places and consumption-based services. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to reinvent themselves and succeed as a digital leader.

Contact:

Mercury Global Partners for MATRIXX Software Natalee Gibson, Managing Director matrixx@mercuryglobalpartners.com +1 720 648 5784

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye